These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 15123732)

  • 1. Chemotherapy for melanoma: the resultant of conflicting vectors.
    Mitchell MS
    J Clin Oncol; 2004 Jun; 22(11):2043-5. PubMed ID: 15123732
    [No Abstract]   [Full Text] [Related]  

  • 2. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo.
    Lev DC; Onn A; Melinkova VO; Miller C; Stone V; Ruiz M; McGary EC; Ananthaswamy HN; Price JE; Bar-Eli M
    J Clin Oncol; 2004 Jun; 22(11):2092-100. PubMed ID: 15123733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypopigmentation in the sites of regressed melanoma metastases after successful dacarbazine therapy.
    Roider E; Schneider J; Flaig MJ; Ruzicka T; Kunte C; Berking C
    Int J Dermatol; 2012 Sep; 51(9):1142-4. PubMed ID: 21913905
    [No Abstract]   [Full Text] [Related]  

  • 4. [At the front line of malignant melanoma, great maneuvers: to cut the road to Bcl2 and "attack with chemotherapy"].
    Bénard J
    Bull Cancer; 1998 Jun; 85(6):520-1. PubMed ID: 9752277
    [No Abstract]   [Full Text] [Related]  

  • 5. Management of metastatic melanoma.
    Tawbi HA; Kirkwood JM
    Semin Oncol; 2007 Dec; 34(6):532-45. PubMed ID: 18083377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy-related myelodysplastic syndrome after alkylating agents and platinum-based therapy for malignant melanoma.
    Nin-Asai R; Sawada M; Matsumoto T; Saito S; Yokota K; Akiyama M
    J Dermatol; 2014 Feb; 41(2):178-9. PubMed ID: 24387309
    [No Abstract]   [Full Text] [Related]  

  • 7. Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine.
    Revskaya E; Jongco AM; Sellers RS; Howell RC; Koba W; Guimaraes AJ; Nosanchuk JD; Casadevall A; Dadachova E
    Clin Cancer Res; 2009 Apr; 15(7):2373-9. PubMed ID: 19293257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
    Bedikian AY; Millward M; Pehamberger H; Conry R; Gore M; Trefzer U; Pavlick AC; DeConti R; Hersh EM; Hersey P; Kirkwood JM; Haluska FG;
    J Clin Oncol; 2006 Oct; 24(29):4738-45. PubMed ID: 16966688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma.
    Treudler R; Georgieva J; Geilen CC; Orfanos CE
    J Am Acad Dermatol; 2004 May; 50(5):783-5. PubMed ID: 15097966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice.
    Thallinger C; Werzowa J; Poeppl W; Kovar FM; Pratscher B; Valent P; Quehenberger P; Joukhadar C
    J Invest Dermatol; 2007 Oct; 127(10):2411-7. PubMed ID: 17508024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alkylating benzamides with melanoma cytotoxicity: experimental chemotherapy in a mouse melanoma model.
    Wolf M; Eskerski H; Bauder-Wüst U; Haberkorn U; Eisenhut M
    Melanoma Res; 2006 Dec; 16(6):487-96. PubMed ID: 17119449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoemulsion preparations of the anticancer drug dacarbazine significantly increase its efficacy in a xenograft mouse melanoma model.
    Tagne JB; Kakumanu S; Nicolosi RJ
    Mol Pharm; 2008; 5(6):1055-63. PubMed ID: 19434855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Phototoxicity of dacarbazine (Deticene) not reinduced by temozolomide (Temodal)].
    Schmutz JL; Barbaud A; Trechot P
    Ann Dermatol Venereol; 2006 May; 133(5 Pt 1):500. PubMed ID: 16760848
    [No Abstract]   [Full Text] [Related]  

  • 14. [Disseminated melanoma treatment].
    Neidhardt-Bérard EM; Négrier S
    Rev Prat; 2004 Jun; 54(11):1210-4. PubMed ID: 15496028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapeutic induced fascial oedema.
    Lim I; Kefford R; Manolios N
    Ann Rheum Dis; 2005 Jan; 64(1):162-3. PubMed ID: 15608322
    [No Abstract]   [Full Text] [Related]  

  • 16. In-transit melanoma: the role of alkylating-agent resistance in regional therapy.
    Grubbs EG; Abdel-Wahab O; Cheng TY; Abdel-Wahab Z; Peterson B; Pruitt SK; Colvin OM; Friedman HS; Tyler DS
    J Am Coll Surg; 2004 Sep; 199(3):419-27. PubMed ID: 15325612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
    Eggermont AM; Kirkwood JM
    Eur J Cancer; 2004 Aug; 40(12):1825-36. PubMed ID: 15288283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oblimersen in the treatment of metastatic melanoma.
    Tarhini AA; Kirkwood JM
    Future Oncol; 2007 Jun; 3(3):263-71. PubMed ID: 17547520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming melanoma drug resistance through metabolic targeting?
    Smalley KS
    Pigment Cell Melanoma Res; 2013 Nov; 26(6):793-5. PubMed ID: 24152044
    [No Abstract]   [Full Text] [Related]  

  • 20. Dacarbazine induced acute myeloid leukemia in melanoma.
    Collins CM; Morgan DS; Mosse C; Sosman J
    Melanoma Res; 2009 Oct; 19(5):337-40. PubMed ID: 19741425
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.